The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK

• Published in: Wellcome open research Vol. 8; p. 111
• Main Authors: Smith, Christopher, Smith, Emma, Chiu, Christopher, Hinton, Jay, Perez Sepulveda, Blanca, Gordon, Melita, Choy, Robert K M, Hill, Peter W S, Meiring, James E, Darton, Thomas C, Carey, Megan E, Cooke, Graham, Gibani, Malick M
• Format: Journal Article
• Language: English
• Published: England Wellcome 2023
• Subjects: eng; Salmonella; Salmonella Typhimurium; Non-Typhoidal Salmonella; Human Challenge Model; Controlled Human Infection Model; Vaccines; Salmonella; Salmonella Typhimurium; Non-Typhoidal Salmonella; Human Challenge Model; Controlled Human Infection Model; Vaccines
• ISSN: 2398-502X; 2398-502X
• DOI: 10.12688/wellcomeopenres.19012.1

Invasive non-typhoidal disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to prevent non-typhoidal (NTS) would represent a valuable public health tool in this setting to avert cases and prevent expansion of antimicrobial resistance. Several NTS and combination typhoidal-NTS vaccine candidates are in early-stage development, although the pathway to licensure is unclear due to challenges in conducting large phase III field trials. Controlled human infection models (CHIM) present an opportunity to accelerate vaccine development for a range of enteric pathogens. Several recent typhoidal CHIMs have been conducted safely and have played pivotal roles in progressing vaccine candidates to pre-qualification and licensure. The Challenge Non-Typhoidal (CHANTS) consortium has been formed with funding from the Wellcome Trust, to deliver the first NTS CHIM, which can act as a platform for future vaccine evaluation. This paper reports the conclusions of a consultation group workshop convened with key stakeholders. The aims of this meeting were to: (1) define the rationale for an NTS CHIM (2) map the NTS vaccine pipeline (3) refine study design and (4) establish potential future use cases.